EFFECTS OF ATORVASTATIN ON ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT DURATION F THE DISEASE

QR Code

EFFECTS OF ATORVASTATIN ON ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT DURATION F THE DISEASE

Aim. To evaluate dynamics of endothelial vasoregulatory function in type 2 diabetic patients after 6 months of combined treatment with atorvastastin 20 mg/day depending on the disease duration and target lipid levels achievement.Material and methods. The total of 161 type 2 diabetic patients with dy...

Full description

Saved in:

Bibliographic Details
Main Authors:	G. A. Batrak, S. E. Miasoedova, O. I. Kelesh
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	diabetes mellitus endothelial vasoregulatory function disease duration atorvastatin
Online Access:	https://www.rpcardio.online/jour/article/view/60
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term low-dose atorvastatin therapy and prevention of macroangiopathy complications in elderly patients with Type 2 diabetes mellitus
by: G. A. Batrak, et al.
Published: (2010-06-01)

THE ASSOCIATION OF DIABETES DURATION WITH THE SEVERITY OF DIABETIC RETINOPATHY
by: Intan Lamy Manao, et al.
Published: (2021-01-01)

SPECIFICS OF LIPID METABOLISM AND ATORVASTATIN EFFICACY IN TYPE 2 DIABETES WITH CARRIAGE OF VARIOUS POLYMORPHISMS OF CHOLESTEROL ETHER CARRYING PROTEIN TaqIB GENE
by: M. V. Kim, et al.
Published: (2015-10-01)

ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CORONARY HEART DISEASE AND TYPE 2 DIABETES MELLITUS
by: M. M. Petina, et al.
Published: (2011-04-01)

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness
by: A. V. Susekov, et al.
Published: (2007-06-01)

Correction of endothelial dysfunction and microcirculation disturbances in patients with essential arterial hypertension and Type 2 diabetes mellitus
by: N. V. Yakutina
Published: (2007-12-01)

Nitric oxide role and endothelial dysfunction development in diabetes mellitus
by: S. G. Dzugkoev, et al.
Published: (1970-01-01)

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin
by: Fei Li, et al.
Published: (2025-07-01)

The impact of perindopril and metformin on the markers of endothelial dysfunction in rats with acute intracerebral hemorrhage and type 2 diabetes mellitus
by: V.I. Zhyliuk, et al.
Published: (2021-12-01)

Factors Affecting HbA1c According to Sleep Duration in Adults with Diabetes
by: Myoungjin Kwon, et al.
Published: (2025-06-01)

Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)
by: M. V. Kim, et al.
Published: (2015-03-01)

ARTERIAL ENDOTHELIAL DYSFUNCTION AND MYOCARDIAL ISCHEMIA IN PATIENTS WITH CARBOHYDRATE METABOLISM DISTURBANCES
by: I. P. Tatarchenko, et al.
Published: (2014-02-01)

Endothelial Dysfunction Diagnostic “Platform” in patients with diabetes mellitus
by: I. A. Khripun, et al.
Published: (2022-03-01)

Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity
by: E. V. Eliseeva, et al.
Published: (1970-01-01)

ENDOTHELIAL-TROPIC AND NEPHROPROTECTIVE EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: M. E. Statsenko, et al.
Published: (2015-09-01)

The effects of exercise intervention on the function of endothelial progenitor cells in atherosclerotic mice with type 2 diabetes mellitus
by: Zheng HUANG, et al.
Published: (2025-06-01)

Oxidative stress and endothelial dysfunction correction with ACE inhibitor therapy in patients with myocardial infarction and Type 2 diabetes mellitus
by: V. S. Zadionchenko, et al.
Published: (2008-10-01)

Relationship of endothelial dysfunction with degree of renal function damage and lipidemic profile in patients with type 2 diabetes mellitus and hypertension.
by: N. O. Pertseva
Published: (2014-09-01)

Lipid and pleiotropic effects of atorvastatin in patients with high cardiovascular risk
by: R. S. Karpov, et al.
Published: (2009-08-01)

The results of correction of endothelial dysfunction in type 2 diabetes mellitus in patients with diabetic retinopathy and associated hypertension
by: L. K. Moshetova, et al.
Published: (2014-07-01)

Analysis of the binary mixtures of amlodipine and atorvastatin by chemometric-spectophotometric method
by: Hayrettin Bulum, et al.
Published: (2025-06-01)

The Role of Endothelial Progenitor Cells (EPCs) and Circulating Endothelial Cells (CECs) as Early Biomarkers of Endothelial Dysfunction in Children with Newly Diagnosed Type 1 Diabetes
by: Milena Jamiołkowska-Sztabkowska, et al.
Published: (2025-07-01)

Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus
by: Yu. N. Belenkov, et al.
Published: (2011-02-01)

Lipid and pleiotropic effects of atorvastatin in patients with acute coronary syndrome
by: A. A. Yalymov, et al.
Published: (1970-01-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
by: A. N. Meshkov
Published: (2016-01-01)

Diabetes duration-specific association of dietary inflammatory index with the risk of mortality among individuals with diabetes
by: Xi Chen, et al.
Published: (2025-06-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report
by: O. V. Tsygankova, et al.
Published: (2021-12-01)

Relationship of morphological changes of blood cells with endothelial function, renal function and lipidemic profile in patients with type 2 diabetes mellitus with suboptimal glycemic control and hypertension
by: Pertseva N.O.
Published: (2016-03-01)

ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE
by: N. G. Gogolashvili
Published: (2018-03-01)

Markers of Endothelial Dysfunction: E-selectin, Endothelin-1 and von Willebrand Factor in Patients with Coronary Heart Disease, Including in Combination with Type 2 Diabetes Mellitus
by: A. V. Zhito, et al.
Published: (2020-01-01)

Dynamics of endothelial dysfunction, nephropathic and dyslipidemic disorders in patients with insufficient glycemic compensation of type 2 diabetes mellitus during 1 year of application of angiotensin II receptor antagonists for hypertension correction.
by: N. O. Pertseva
Published: (2014-11-01)

TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE
by: T. P. Bardymova, et al.
Published: (2017-02-01)

Histopathological aspects of endothelial dysfunction in the vessels of brain microcirculation in case of diabetic encephalopathy
by: Pashkovska N.V.
Published: (2008-01-01)

ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE
by: V. E. Oleynikov, et al.
Published: (2015-11-01)

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

The role of «old age proteins» and endotelial dysfunction markers in diabetic foot syndrome development
by: R. I. Damdinov, et al.
Published: (2021-08-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

Atorvastatin: evidence base 15 years later
by: A. V. Susekov, et al.
Published: (2011-06-01)